Plasma-exchange therapy slows Alzheimer progression by more than half in clinical data

The AMBAR program uses plasma-exchange to extract plasma, replace it with a 5% albumin solution, and thereby clear circulating beta-amyloid that contributes to Alzheimer’s plaques. Clinical observations presented at the annual meeting of the Sociedad Española de Neurología in Sevilla reveal that patients with mild or moderate disease experience a 61% reduction in disease progression versus untreated peers. investigators report gains in executive decision-making, language abilities and memory retention, alongside high scores on quality-of-life assessments from caregivers.

The technique builds on standard apheresis methods and follows guidelines issued by the American Society for Apheresis. To date, the procedure has been carried out in dozens of hospitals in Spain and the United States, with a substantial number of sessions performed at the Ace Alzheimer Center Barcelona, which also runs multiple other Alzheimer trials.